CareDx, Inc (CDNA)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, CareDx, Inc keeps $84 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 3
in 54 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
CareDx topped expectations on both the top and bottom line in the second fiscal quarter of 2026, which it reported on July 30, 2026, as revenue rose 52.2% to roughly $131.9 million (up from about $86.7 million a year ago) alongside adjusted EPS of $0.37 versus -$0.16 a year ago. On the consensus comparison, adjusted EPS of $0.37 topped the $0.23 estimate (+59%), while revenue of $131.9 million topped the $114.0 million estimate (+15.7%). The transplant-focused diagnostics and research software provider generated gross profit of about $97.0 million, with gross margin at roughly 74%, and it produced operating cash flow of about $30.6 million. For the next period, consensus calls for EPS of $0.24 on revenue of $121.9 million.
About CareDx, Inc
CareDx, Inc. trades on the NASDAQ as CDNA and operates in transplant-focused medical diagnostics and research software. The company develops diagnostic and management tools for transplant recipients, serving healthcare providers globally through direct sales and distributor networks, and generated $379.8 million of revenue in FY2025.
Today's Snapshot
The session opened with CDNA 1.7% lower at 49.19, while its sector was flat.
Trading Volume
Below 10d avg (1.0M)
208.3K
vs S&P 500 Today
Outperforming Market
+2.37%
Updated: September 10, 2026 at 15:12 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$28.41 - $50.01Buy
- RSI (14)64.19Neutral
- Stochastic %K (14, 3, 3)60.04Neutral
- MACD Level (12, 26)2.35Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.